A 42-year-old woman with right breast cancer cT4dN2M0 HR +, HER2 +, undergoes mastectomy with axillary lymphadenectomy after neoadjuvant chemotherapy. During adjuvant treatment with trastuzumab and hormone therapy, the patient develops multiple symptomatic encephalic metastases. She undergoes panencephalic radiotherapy and begins chemotherapy with capecitabine and lapatinib. After three months of well tolerated therapy, an important volumetric response of encephalic metastases is observed, with regression of neurological symptoms.
Galanti D., Vaccaro G., Cipolla C., Graceffa G., Valerio M.R. (2020). Lapatinib activity in a patient with encephalic metastases from trastuzumab-resistant her-2 positive breast cancer. ACTA MEDICA MEDITERRANEA, 36(5), 2985-2987 [10.19193/0393-6384_2020_5_458].
Lapatinib activity in a patient with encephalic metastases from trastuzumab-resistant her-2 positive breast cancer
Vaccaro G.;Cipolla C.;Graceffa G.;Valerio M. R.
2020-01-01
Abstract
A 42-year-old woman with right breast cancer cT4dN2M0 HR +, HER2 +, undergoes mastectomy with axillary lymphadenectomy after neoadjuvant chemotherapy. During adjuvant treatment with trastuzumab and hormone therapy, the patient develops multiple symptomatic encephalic metastases. She undergoes panencephalic radiotherapy and begins chemotherapy with capecitabine and lapatinib. After three months of well tolerated therapy, an important volumetric response of encephalic metastases is observed, with regression of neurological symptoms.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Acta Med Medit 2020 - LAPATINIB ACTIVITY.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
208.68 kB
Formato
Adobe PDF
|
208.68 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
